Search

Your search keyword '"Volkinshtein, Rita"' showing total 7 results
Start Over Author "Volkinshtein, Rita"
7 results on '"Volkinshtein, Rita"'

1. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Author

Guttman, Mark, Raymond, Lynn, Mendis, Tilak, Suchowersky, Oksana, Corey-Bloom, Jody, Geschwind, Michael D, Marshall, Frederick J, Marder, Karen S, Nance, Martha, Racette, Brad, Bang, Jee, Segro, Victoria, McDonell, Katherine, Kamholz, John, LeDoux, Mark S, Sanchez-Ramos, Juan, DeMichele, Giuseppe, Mariotti, Caterina, Squitieri, Ferdinando, Soliveri, Paola, Cortelli, Pietro, Muñoz García, José Esteban, Kulisevsky Bojarski, Jaime, López-Sendón Moreno, José Luis, Berganzo Corrales, Koldo, Cubo, Esther, García Moreno, José Manuel, Orth, Michael, Priller, Josef, Saft, Carsten, Weindl, Adolf, Winkler, Juergen, Craufurd, David, Miedzybrodzka, Zofia, Rickards, Hugh, Davies, Rhys Richard, Lahiri, Nayana, Ruddy, Deborah, Komati, Suresh K, Quarrell, Oliver William John, Correira Guedes, Leonor, Roos, Raymund A C, Zalyalova, Zuleykha, Illarioshkin, Sergey, Gustov, Aleksandr, Klempir, Jiri, Reilmann, Ralf, Anderson, Karen E, Feigin, Andrew, Tabrizi, Sarah J, Leavitt, Blair R, Stout, Julie C, Piccini, Paola, Schubert, Robin, Loupe, Pippa, Wickenberg, Anna, Borowsky, Beth, Rynkowski, Gail, Volkinshtein, Rita, Li, Thomas, Savola, Juha-Matti, Hayden, Michael, and Gordon, Mark Forrest

Published
2024
Full Text
View/download PDF

2. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Author

Reilmann, Ralf, primary, Anderson, Karen E, additional, Feigin, Andrew, additional, Tabrizi, Sarah J, additional, Leavitt, Blair R, additional, Stout, Julie C, additional, Piccini, Paola, additional, Schubert, Robin, additional, Loupe, Pippa, additional, Wickenberg, Anna, additional, Borowsky, Beth, additional, Rynkowski, Gail, additional, Volkinshtein, Rita, additional, Li, Thomas, additional, Savola, Juha-Matti, additional, Hayden, Michael, additional, Gordon, Mark Forrest, additional, Guttman, Mark, additional, Raymond, Lynn, additional, Mendis, Tilak, additional, Suchowersky, Oksana, additional, Corey-Bloom, Jody, additional, Geschwind, Michael D, additional, Marshall, Frederick J, additional, Marder, Karen S, additional, Nance, Martha, additional, Racette, Brad, additional, Bang, Jee, additional, Segro, Victoria, additional, McDonell, Katherine, additional, Kamholz, John, additional, LeDoux, Mark S, additional, Sanchez-Ramos, Juan, additional, DeMichele, Giuseppe, additional, Mariotti, Caterina, additional, Squitieri, Ferdinando, additional, Soliveri, Paola, additional, Cortelli, Pietro, additional, Muñoz García, José Esteban, additional, Kulisevsky Bojarski, Jaime, additional, López-Sendón Moreno, José Luis, additional, Berganzo Corrales, Koldo, additional, Cubo, Esther, additional, García Moreno, José Manuel, additional, Orth, Michael, additional, Priller, Josef, additional, Saft, Carsten, additional, Weindl, Adolf, additional, Winkler, Juergen, additional, Craufurd, David, additional, Miedzybrodzka, Zofia, additional, Rickards, Hugh, additional, Davies, Rhys Richard, additional, Lahiri, Nayana, additional, Ruddy, Deborah, additional, Komati, Suresh K, additional, Quarrell, Oliver William John, additional, Correira Guedes, Leonor, additional, Roos, Raymund A C, additional, Zalyalova, Zuleykha, additional, Illarioshkin, Sergey, additional, Gustov, Aleksandr, additional, and Klempir, Jiri, additional

Published
2024
Full Text
View/download PDF

3. sj-pdf-1-msj-10.1177_13524585211032803 – Supplemental material for CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Author

Comi, Giancarlo, Dadon, Yuval, Sasson, Nissim, Steinerman, Joshua R, Knappertz, Volker, Vollmer, Timothy L, Boyko, Alexey, Vermersch, Patrick, Ziemssen, Tjalf, Montalban, Xavier, Lublin, Fred D, Rocca, Maria A, Volkinshtein, Rita, Rubinchick, Svetlana, Halevy, Nitsan, and Filippi, Massimo

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_13524585211032803 for CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis by Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf Ziemssen, Xavier Montalban, Fred D Lublin, Maria A Rocca, Rita Volkinshtein, Svetlana Rubinchick, Nitsan Halevy and Massimo Filippi in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

4. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Author

Comi, Giancarlo, primary, Dadon, Yuval, additional, Sasson, Nissim, additional, Steinerman, Joshua R, additional, Knappertz, Volker, additional, Vollmer, Timothy L, additional, Boyko, Alexey, additional, Vermersch, Patrick, additional, Ziemssen, Tjalf, additional, Montalban, Xavier, additional, Lublin, Fred D, additional, Rocca, Maria A, additional, Volkinshtein, Rita, additional, Rubinchick, Svetlana, additional, Halevy, Nitsan, additional, and Filippi, Massimo, additional

Published
2021
Full Text
View/download PDF

5. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

Author

Comi, Giancarlo, Dadon, Yuval, Sasson, Nissim, Steinerman, Joshua R, Knappertz, Volker, Vollmer, Timothy L, Boyko, Alexey, Vermersch, Patrick, Ziemssen, Tjalf, Montalban, Xavier, Lublin, Fred D, Rocca, Maria A, Volkinshtein, Rita, Rubinchick, Svetlana, Halevy, Nitsan, and Filippi, Massimo

Subjects
MAGNETIC resonance imaging, MULTIPLE sclerosis, DISEASE relapse, CONCERTO
Abstract

Background: Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective: Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized 1:1:1 to receive once-daily oral laquinimod 0.6 or 1.2 mg or placebo for ⩽24 months (n = 727, n = 732, and n = 740, respectively). Primary endpoint was time to 3-month confirmed disability progression (CDP). The laquinimod 1.2-mg dose arm was discontinued (1 January 2016) due to cardiovascular events at high doses. Safety was monitored throughout the study. Results: CONCERTO did not meet the primary endpoint of significant effect with laquinimod 0.6-mg versus placebo on 3-month CDP (hazard ratio: 0.94; 95% confidence interval: 0.67–1.31; p = 0.706). Secondary endpoint p values were nominal and non-inferential. Laquinimod 0.6 mg demonstrated 40% reduction in percent brain volume change from baseline to Month 15 versus placebo (p < 0.0001). The other secondary endpoint, time to first relapse, and annualized relapse rate (an exploratory endpoint) were numerically lower (both, p = 0.0001). No unexpected safety findings were reported with laquinimod 0.6 mg. Conclusion: Laquinimod 0.6 mg demonstrated only nominally significant effects on clinical relapses and magnetic resonance imaging (MRI) outcomes and was generally well tolerated. Clinical trial registration number: ClinicalTrials.gov (NCT01707992). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. J05 Legato-hd study: a phase 2 study assessing the efficacy and safety of laquinimod as a treatment for huntington disease

Author

Reilmann, Ralf, primary, Gordon, Mark Forrest, additional, Anderson, Karen E, additional, Feigin, Andrew, additional, Tabrizi, Sarah J, additional, Leavitt, Blair R, additional, Stout, Julie C, additional, Piccini, Paola, additional, Rynkowski, Gail, additional, Volkinshtein, Rita, additional, and Savola, Juha, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results